摘要
目的探究重组人白介素⁃11(rhIL⁃11)联合利妥昔单克隆抗体对免疫性血小板减少症患者NK细胞、色氨酸代谢的影响。方法选取2018年1月至2022年3月于秦皇岛市第一医院接受治疗的免疫性血小板减少症患者136例,按照随机数字法分为抗体治疗组(利妥昔单克隆抗体)和联合治疗组(rhIL⁃11联合利妥昔单克隆抗体)各68例。检测并对比两组患者γ⁃干扰素(INF⁃γ)、白细胞介素⁃4(IL⁃4)水平、T淋巴细胞亚群(CD4+、CD8+)水平、NK细胞、Bright亚群、Din亚群数量、血清色氨酸、犬尿氨酸浓度,对比两组患者治疗有效率和不良反应率。结果与抗体治疗组相比,联合治疗组患者INF⁃γ水平较低,IL⁃4水平较高,差异有统计学意义(t=3.149、2.680;P<0.05);与抗体治疗组相比,联合治疗组CD4+水平较高,CD8+水平较低,差异有统计学意义(t=12.090、8.838;P<0.05);与抗体治疗组相比,联合治疗组NK细胞、Bright亚群、Din亚群数量较多,差异有统计学意义(t=5.310、2.276、5.995;P<0.05);与抗体治疗组相比,联合治疗组患者血色氨酸水平较低,犬尿氨酸水平较高(t=11.600、2.120;P<0.05);与抗体治疗组相比,联合治疗组治疗总有效率上升(P<0.05)。结论使用rhIL⁃11联合利妥昔单克隆抗体能够改善免疫性血小板减少症患者T淋巴细胞亚群、NK细胞及其亚群水平,效果显著。
Objective To investigate the effect of recombinant human interleukin⁃11(rhIL⁃11)combined with rituximab on NK cells and tryptophan metabolism in patients with immune thrombocytopenia.Methods A total of 136 immune thrombocytopenia patients treated in the Qinhuangdao First Hospital from September 2018 to September 2022 were divided into the antibody treatment group(rituximab monoclonal anti⁃body)and the combination treatment group(rhIL⁃11 combined with rituximab monoclonal antibody)accord⁃ing to random number method,and 68 cases were selected.In the two groups of patients,γ⁃interferon(INF⁃γ),interleukin⁃4(IL⁃4),T lymphocytes(CD4+,CD8+),NK cells,Bright,Din number,serum tryptophan,ca⁃nine urenine concentration to compare the treatment response rate and adverse reaction rate of the two groups.Results Compared to the antibody⁃treated group,Patients in the combination treatment group had lower INF⁃γlevels,the higher level of IL⁃4,the difference was statistically significant(t=3.149,2.680;P<0.05).Com⁃pared with the antibody treatment group,the combined treatment group had higher CD4+levels and lower CD8+levels,with statistically significant differences(t=12.090,8.838;P<0.05).Compared with the anti⁃body therapy group,the combination therapy group had a higher number of NK cells,Bright subgroups,and Din subgroups,with statistically significant differences(t=5.310,2.276,5.995;P<0.05).Compared to the antibody⁃treated group,Patients in the combination treatment group had lower blood tryptophan levels,high urine level(t=11.600,2.120;P<0.05).Compared with the antibody therapy group,the total effective rate of the combination therapy group increased(P<0.05).Conclusion The use of rhIL⁃11 combined with rituximab monoclonal antibody can significantly improve the levels of T lymphocyte subsets,NK cells,and their subsets in patients with immune thrombocytopenia.
作者
于艺冰
张琳
孔艳
王晶
陈晨
李峰敏
YU Yibing;ZHANG Lin;KONG Yan;WANG Jing;CHEN Chen;LI Fengmin(Department of Hematology,the First Hospital of Qinhuangdao,Qinhuangdao,Heibei,China,066000)
出处
《分子诊断与治疗杂志》
2023年第7期1261-1264,1269,共5页
Journal of Molecular Diagnostics and Therapy
基金
河北省卫计委医学科学研究重点课题计划(20181197)。
